Abstract
Objective: Troglitazone is a useful new thiazolidinedione oral antidiabetic agent, but it is unpredictably hepatotoxic in about 1.9% of patients. In vitro studies of drug interactions are important in understanding the basis for the pharmacological and toxicological actions of drugs. In the present study, we investigated whether troglitazone inhibits uridine diphosphate (UDP)-glucuronosyltransferase 1A6 (UGT1A6) activity. Methods: Human cDNA-expressed UGT1A6 was co-incubated with troglitazone (inhibitor) and 1-naphthol (substrate). The glucuronidation of 1-naphthol was determined to establish a 50% inhibitory concentration (IC50) and an inhibition (Ki) value. Results: Troglitazone inhibited UGT1A6 activity with an IC50 of 28 µM at a 1-naphthol concentration of 20 µM. The inhibition was a mixed-type mechanism with a Ki value of 20 µM. Conclusion: Inhibitory effect of troglitazone is weak, however, co-administration of troglitazone might carry a drug concentration into the toxic range when the concentration approaches a threshold of toxicity by an inherent reduction of UGT1A6 activity.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Accepted revised in form: 22 November 2000
Electronic Publication
Rights and permissions
About this article
Cite this article
Ito, M., Yamamoto, K., Sato, H. et al. Inhibitory effect of troglitazone on glucuronidation catalyzed by human uridine diphosphate-glucuronosyltransferase 1A6. Eur J Clin Pharmacol 56, 893–895 (2001). https://doi.org/10.1007/s002280000252
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s002280000252